ACTRIMS 2023: CNM-Au8 bound for Phase 3 testing after positive data | Multiple Sclerosis News Today
The upcoming global Phase 3 clinical trial will test CNM-Au8's effect on MS disease progression that occurs independently of relapse activity.
San Diego United States Michael Hotchkin Benjamin Greenberg Clene Nanomedicine Southwestern Medical Center
Source: multiplesclerosisnewstoday.com